Global medical technology company Becton, Dickinson, and Company (BD; Franklin Lakes, NJ) has closed on its $350 million purchase of the approximately 93.5% of outstanding shares in TriPath Imaging (Burlington, NC), a leading player in the increasingly crowded market for cervical cancer screening. BD has held a 6.5% equity interest in TriPath since 2001, when the two companies began their ongoing collaboration to discover cancer biomarkers. BD’s bid of $9.25 in cash per share of TriPath represented at 81% premium to the company’s closing share price on the day the bid was filed.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

January 2007 - Table of Contents

LIR January 2007 (full PDF issue)

Competitive Bidding Demo in Holding Pattern Awaiting OMB’s OK

Sonic to Acquire American Esoteric Laboratories for $180M

LabCorp Buys Kansas Lab

What Does ’07 Hold for LabCorp? LIR’s Interview With New CEO Dave King

Lab Industry Awaits First Domino of Competitive Bidding Project to Tip

Spotlight on Pap Testing: Monolayer Testing to Take 100% of Market in ’07?

BD Closes on $350m TriPath Acquisition

Luminex to Buy Tm Bioscience for $37.9M

Aetna Contracts With Genomic Health for Oncotype DX

Lab Stocks Rise 4%; Clarient and Genomic Health Soar 27%

Integrating MDx Conference